CTLA4 and renal cell carcinoma: Because anti-PD-1 antibody treatment is already used for patients with RCC exhibiting recurrence or metastasis and because combination therapies, such as anti-PD-1 antibody plus anti-CTLA4 antibody treatment or anti-PD-1 antibody plus axitinib treatment, have also been applied clinically in the treatment of RCC [33], combination therapy with disulfiram may be a promising approach.